Guardant Health - GH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $41.30
  • Forecasted Upside: 126.18%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$18.26
▼ -0.42 (-2.25%)

This chart shows the closing price for GH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardant Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GH

Analyst Price Target is $41.30
▲ +126.18% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $41.30, with a high forecast of $55.00 and a low forecast of $27.00. The average price target represents a 126.18% upside from the last price of $18.26.

This chart shows the closing price for GH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Guardant Health. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/20/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/18/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/18/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/17/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/15/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/13/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2024GuggenheimReiterated RatingNeutralLow
2/26/2024Piper SandlerLower TargetOverweight ➝ Overweight$40.00 ➝ $30.00Low
2/23/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$60.00 ➝ $45.00Low
2/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$50.00 ➝ $45.00Low
1/29/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$43.00 ➝ $37.00Low
12/14/2023GuggenheimInitiated CoverageNeutralLow
12/13/2023Wolfe ResearchInitiated CoveragePeer PerformLow
11/13/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$27.00Low
11/8/2023Morgan StanleyLower TargetOverweight ➝ Overweight$55.00 ➝ $50.00Low
10/20/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$52.00 ➝ $45.00Low
10/2/2023CitigroupReiterated RatingBuy ➝ Buy$50.00Low
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$34.00Low
9/27/2023Piper SandlerUpgradeNeutral ➝ Overweight$40.00Low
9/8/2023William BlairReiterated RatingOutperformLow
8/8/2023Piper SandlerBoost TargetNeutral ➝ Neutral$30.00 ➝ $40.00Low
8/7/2023Morgan StanleyLower TargetOverweight ➝ Overweight$60.00 ➝ $55.00Low
8/4/2023CitigroupBoost TargetBuy ➝ Buy$40.00 ➝ $50.00Low
5/26/2023CitigroupUpgradeNeutral ➝ Buy$28.00 ➝ $40.00Low
5/15/2023Piper SandlerLower Target$35.00 ➝ $30.00Low
5/10/2023Credit Suisse GroupLower Target$60.00 ➝ $55.00Low
5/5/2023UBS GroupInitiated CoverageBuy$40.00Low
3/9/2023CitigroupDowngradeBuy ➝ Neutral$60.00 ➝ $33.00Low
3/3/2023Piper SandlerLower TargetNeutral$50.00 ➝ $35.00Low
2/27/2023Morgan StanleyLower TargetOverweight$73.00 ➝ $66.00Low
2/24/2023BTIG ResearchLower TargetBuy$60.00 ➝ $50.00Low
2/24/2023Credit Suisse GroupLower TargetOutperform$70.00 ➝ $60.00Low
2/24/2023Canaccord Genuity GroupLower TargetBuy$65.00 ➝ $60.00Low
2/24/2023CowenLower TargetOutperform$70.00 ➝ $53.00Low
2/24/2023JPMorgan Chase & Co.Lower TargetOverweight$75.00 ➝ $65.00Low
2/21/2023Morgan StanleyLower TargetOverweight$80.00 ➝ $73.00Low
2/16/2023StephensReiterated RatingOverweight$63.00Low
2/6/2023The Goldman Sachs GroupLower TargetBuy$70.00 ➝ $45.00Low
1/4/2023ScotiabankInitiated CoverageSector Outperform$36.00Low
12/16/2022Bank of AmericaBoost Target$65.00 ➝ $70.00Low
12/16/2022CowenLower Target$83.00 ➝ $70.00Low
12/16/2022BTIG ResearchLower Target$80.00 ➝ $60.00Low
12/16/2022CitigroupLower Target$80.00 ➝ $60.00Low
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$100.00 ➝ $85.00Low
11/7/2022StephensLower TargetOverweight$99.00 ➝ $90.00Low
11/4/2022The Goldman Sachs GroupLower TargetBuy$80.00 ➝ $70.00Low
11/4/2022CowenLower Target$110.00 ➝ $83.00Low
11/4/2022CowenLower Target$110.00 ➝ $83.00Low
11/4/2022Credit Suisse GroupLower TargetOutperform$80.00 ➝ $70.00N/A
11/4/2022CitigroupLower Target$100.00 ➝ $80.00Low
11/1/2022Piper SandlerDowngradeOverweight ➝ Neutral$65.00 ➝ $50.00Low
10/19/2022Craig HallumInitiated CoverageBuy$88.00Low
10/5/2022StephensInitiated CoverageOverweight$99.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$80.00Low
8/8/2022The Goldman Sachs GroupLower TargetBuy$90.00 ➝ $80.00Low
8/8/2022Morgan StanleyLower TargetOverweight$85.00 ➝ $80.00Low
8/1/2022OTR GlobalDowngradePositiveLow
6/2/2022Piper SandlerInitiated CoverageOverweight$65.00High
5/6/2022CitigroupLower Target$120.00 ➝ $100.00High
2/24/2022Stifel NicolausLower TargetBuy$160.00 ➝ $130.00High
2/24/2022CowenLower TargetOutperform$170.00 ➝ $110.00High
2/24/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$180.00 ➝ $165.00High
2/24/2022Morgan StanleyLower TargetOverweight$125.00 ➝ $120.00High
2/24/2022Wells Fargo & CompanyLower TargetOverweight$150.00 ➝ $115.00High
2/24/2022CitigroupLower TargetBuy$180.00 ➝ $120.00High
2/24/2022SVB LeerinkLower TargetOutperform$170.00 ➝ $140.00High
2/15/2022Morgan StanleyLower TargetOverweight$150.00 ➝ $125.00Low
11/5/2021BTIG ResearchReiterated RatingBuy$159.00Low
11/5/2021SVB LeerinkLower TargetOutperform$180.00 ➝ $170.00High
6/21/2021Wells Fargo & CompanyBoost TargetOverweight$145.00 ➝ $160.00Low
6/15/2021Raymond JamesInitiated CoverageMarket PerformHigh
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
5/27/2021William BlairReiterated RatingBuyLow
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00Low
5/23/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021BTIG ResearchBoost TargetBuy$145.00 ➝ $160.00Medium
5/7/2021Morgan StanleyLower TargetOverweight$175.00 ➝ $160.00High
2/26/2021Morgan StanleyBoost TargetOverweight$130.00 ➝ $175.00Medium
2/25/2021CitigroupBoost TargetBuy$155.00 ➝ $190.00High
2/25/2021CowenBoost TargetOutperform$140.00 ➝ $190.00High
1/20/2021SVB LeerinkBoost TargetOutperform$150.00 ➝ $190.00Medium
1/11/2021Stifel NicolausInitiated CoverageBuy$175.00High
12/17/2020BTIG ResearchBoost TargetBuy$132.00 ➝ $145.00High
12/16/2020Smith Barney CitigroupBoost Target$145.00 ➝ $155.00Low
12/11/2020SVB LeerinkBoost TargetOutperform$130.00 ➝ $150.00High
11/12/2020William BlairReiterated RatingOutperformLow
11/9/2020Morgan StanleyBoost TargetOverweight$110.00 ➝ $130.00Medium
11/6/2020JPMorgan Chase & Co.Boost TargetOverweight$120.00 ➝ $135.00Medium
9/9/2020Morgan StanleyInitiated CoverageOverweight$110.00High
6/11/2020BTIG ResearchInitiated CoverageBuy$100.00Low
5/8/2020SVB LeerinkReiterated RatingBuy$125.00 ➝ $130.00High
5/8/2020CitigroupBoost TargetBuy$100.00 ➝ $110.00High
4/23/2020SVB LeerinkLower TargetOutperform$130.00 ➝ $125.00Medium
2/21/2020GuggenheimInitiated CoverageBuy$103.00Medium
1/6/2020CitigroupInitiated CoverageBuy$100.00High
11/8/2019William BlairReiterated RatingOutperformLow
8/7/2019CowenSet TargetBuy$110.00High
8/7/2019JPMorgan Chase & Co.Boost TargetOverweight$90.00 ➝ $135.00High
5/10/2019JPMorgan Chase & Co.Boost TargetOverweight$85.00 ➝ $90.00High
(Data available from 4/12/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/15/2023
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/15/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/14/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
12/14/2023
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
1/13/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/12/2024
  • 12 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
3/13/2024
  • 11 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
4/12/2024

Current Sentiment

  • 11 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $18.26
Low: $17.96
High: $18.58

50 Day Range

MA: $19.78
Low: $17.13
High: $23.23

52 Week Range

Now: $18.26
Low: $16.92
High: $41.06

Volume

1,307,620 shs

Average Volume

1,891,911 shs

Market Capitalization

$2.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardant Health?

The following Wall Street analysts have issued stock ratings on Guardant Health in the last year: Canaccord Genuity Group Inc., Citigroup Inc., Credit Suisse Group AG, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Sanford C. Bernstein, The Goldman Sachs Group, Inc., UBS Group AG, William Blair, and Wolfe Research.
View the latest analyst ratings for GH.

What is the current price target for Guardant Health?

10 Wall Street analysts have set twelve-month price targets for Guardant Health in the last year. Their average twelve-month price target is $41.30, suggesting a possible upside of 126.2%. Credit Suisse Group AG has the highest price target set, predicting GH will reach $55.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $27.00 for Guardant Health in the next year.
View the latest price targets for GH.

What is the current consensus analyst rating for Guardant Health?

Guardant Health currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GH.

What other companies compete with Guardant Health?

Other companies that are similar to Guardant Health include Veracyte, RadNet, Fortrea, Viridian Therapeutics and Fulgent Genetics. Learn More about companies similar to Guardant Health.

How do I contact Guardant Health's investor relations team?

Guardant Health's physical mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company's listed phone number is (855) 698-8887 and its investor relations email address is [email protected]. The official website for Guardant Health is www.guardanthealth.com. Learn More about contacing Guardant Health investor relations.